Intranasal C3a treatment ameliorates cognitive impairment in a mouse model of neonatal hypoxic-ischemic brain injury.

In conclusion, our results reveal that brief pharmacological treatment with C3a using a clinically feasible non-invasive mode of administration ameliorates HI-induced cognitive impairment. Intranasal administration is a plausible route to deliver C3a into the brain of asphyxiated infants at high risk of developing hypoxic-ischemic encephalopathy.
PMID: 28062175 [PubMed - as supplied by publisher]

Source: Experimental Neurology - January 2, 2017 Category: Neurology Authors: Morán J, Stokowska A, Walker FR, Mallard C, Hagberg H, Pekna M Tags: Exp Neurol Source Type: research